Literature DB >> 27060634

Immunocytokines for cancer treatment: past, present and future.

Dario Neri1, Paul M Sondel2.   

Abstract

Immunocytokines are antibody-cytokine fusion proteins, with the potential to preferentially localize on tumor lesions and to activate anticancer immunity at the site of disease. Various tumor targets (e.g., cell membrane antigens and extracellular matrix components) and antibody formats (e.g., intact IgG and antibody fragments) have been considered for immunocytokine development and some products have advanced to clinical trials. In this review, we present relevant concepts and strategies for the design and use of anticancer immunocytokine products. In addition, we discuss emerging strategies for the pharmaceutical development and clinical application of this promising class of biopharmaceuticals.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27060634      PMCID： PMC5215124          DOI： 10.1016/j.coi.2016.03.006

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  63 in total

1.  Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Authors:  Suzanne Shusterman; Wendy B London; Stephen D Gillies; Jacquelyn A Hank; Stephan D Voss; Robert C Seeger; C Patrick Reynolds; Jennifer Kimball; Mark R Albertini; Barrett Wagner; Jacek Gan; Jens Eickhoff; Kenneth B DeSantes; Susan L Cohn; Toby Hecht; Brian Gadbaw; Ralph A Reisfeld; John M Maris; Paul M Sondel
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

Review 2.  Antibody fusions with immunomodulatory proteins for cancer therapy.

Authors:  Dafne Müller
Journal:  Pharmacol Ther       Date:  2015-07-03       Impact factor: 12.310

3.  The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.

Authors:  Chiara Catania; Michela Maur; Rossana Berardi; Andrea Rocca; Anna Maria Di Giacomo; Gianluca Spitaleri; Cristina Masini; Chiara Pierantoni; Reinerio González-Iglesias; Giulia Zigon; Annaelisa Tasciotti; Leonardo Giovannoni; Valeria Lovato; Giuliano Elia; Hans D Menssen; Dario Neri; Stefano Cascinu; Pier Franco Conte; Filippo de Braud
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

4.  Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily.

Authors:  Teresa Hemmerle; Christian Hess; Dario Venetz; Dario Neri
Journal:  J Biotechnol       Date:  2013-12-30       Impact factor: 3.307

5.  A critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution data.

Authors:  Teresa Hemmerle; Sarah Wulhfard; Dario Neri
Journal:  Protein Eng Des Sel       Date:  2012-09-12       Impact factor: 1.650

6.  Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.

Authors:  Catharina M L Zegers; Nicolle H Rekers; Dana H F Quaden; Natasja G Lieuwes; Ala Yaromina; Wilfred T V Germeraad; Lotte Wieten; Erik A L Biessen; Louis Boon; Dario Neri; Esther G C Troost; Ludwig J Dubois; Philippe Lambin
Journal:  Clin Cancer Res       Date:  2014-12-31       Impact factor: 12.531

7.  Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.

Authors:  Barbara Carnemolla; Laura Borsi; Enrica Balza; Patrizia Castellani; Raffaella Meazza; Alexander Berndt; Silvano Ferrini; Hartwig Kosmehl; Dario Neri; Luciano Zardi
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

8.  An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.

Authors:  Stephen D Gillies; Yan Lan; Steven Williams; Frank Carr; Stephen Forman; Andrew Raubitschek; Kin-Ming Lo
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

9.  Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.

Authors:  Richard K Yang; Nicholas A Kalogriopoulos; Alexander L Rakhmilevich; Erik A Ranheim; Songwon Seo; Kyungmann Kim; Kory L Alderson; Jacek Gan; Ralph A Reisfeld; Stephen D Gillies; Jacquelyn A Hank; Paul M Sondel
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

10.  Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.

Authors:  Erik E Johnson; Brett H Yamane; Ilia N Buhtoiarov; Hillary D Lum; Alexander L Rakhmilevich; David M Mahvi; Stephen D Gillies; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531
View more
  46 in total

Review 1.  Next generation antibody drugs: pursuit of the 'high-hanging fruit'.

Authors:  Paul J Carter; Greg A Lazar
Journal:  Nat Rev Drug Discov       Date:  2017-12-01       Impact factor: 84.694

Review 2.  Mechanisms and consequences of Jak-STAT signaling in the immune system.

Authors:  Alejandro V Villarino; Yuka Kanno; John J O'Shea
Journal:  Nat Immunol       Date:  2017-03-22       Impact factor: 25.606

Review 3.  Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity.

Authors:  Dario Neri
Journal:  Cancer Immunol Res       Date:  2019-03       Impact factor: 11.151

4.  Targeted Delivery of TNF Potentiates the Antibody-Dependent Cell-Mediated Cytotoxicity of an Anti-Melanoma Immunoglobulin.

Authors:  Patrizia Murer; Jonathan D Kiefer; Louis Plüss; Mattia Matasci; Sandra L Blümich; Marco Stringhini; Dario Neri
Journal:  J Invest Dermatol       Date:  2018-12-10       Impact factor: 8.551

Review 5.  Delivering safer immunotherapies for cancer.

Authors:  Lauren Milling; Yuan Zhang; Darrell J Irvine
Journal:  Adv Drug Deliv Rev       Date:  2017-05-22       Impact factor: 15.470

6.  Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells.

Authors:  Cornelia Hutmacher; Nicolás Gonzalo Núñez; Anna Rita Liuzzi; Burkhard Becher; Dario Neri
Journal:  Cancer Immunol Res       Date:  2019-02-19       Impact factor: 11.151

7.  Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy.

Authors:  Lior Nissim; Ming-Ru Wu; Erez Pery; Adina Binder-Nissim; Hiroshi I Suzuki; Doron Stupp; Claudia Wehrspaun; Yuval Tabach; Phillip A Sharp; Timothy K Lu
Journal:  Cell       Date:  2017-10-19       Impact factor: 41.582

8.  Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.

Authors:  Anja Sophie Schmid; Diana Tintor; Dario Neri
Journal:  J Biotechnol       Date:  2018-02-10       Impact factor: 3.307

9.  Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.

Authors:  Roberto De Luca; Dario Neri
Journal:  Cancer Immunol Immunother       Date:  2018-07-04       Impact factor: 6.968

10.  Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.

Authors:  Roberto De Luca; Alex Soltermann; Francesca Pretto; Catherine Pemberton-Ross; Giovanni Pellegrini; Sarah Wulhfard; Dario Neri
Journal:  Mol Cancer Ther       Date:  2017-07-17       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.